Savara Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing was signed March 30, 2023. Savara is a clinical-stage biopharmaceutical company with no product revenue; its lead program is inhaled molgramostim for autoimmune pulmonary alveolar proteinosis (aPAP).
Business context and development
Molgramostim is in the Phase 3 IMPALA-2 trial, a 48-week, placebo-controlled study planned for approximately 160 patients. The primary endpoint is change from baseline in percent-predicted DLCO; the primary efficacy assessment is at week 24, with efficacy and safety followed through week 48. Management reported the trial was on track and projected topline data by the end of the second quarter of 2024.
The candidate has FDA Fast Track, Breakthrough Therapy, and Orphan Drug designations, plus UK designations. These do not guarantee approval. Savara reported that the earlier IMPALA trial missed its primary endpoint, although management highlighted favorable results on several secondary and exploratory measures. There is no approved medicine for aPAP; whole-lung lavage is the current standard of care.
Financial and operating metrics
| Metric | 2022 | 2021 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $27.9 million | $29.0 million |
| General and administrative expense | $10.9 million | $12.4 million |
| Total operating expenses | $38.8 million | $41.5 million |
| Net loss | $38.2 million | $43.0 million |
| Basic and diluted loss per share | $0.25 | $0.32 |
| Net cash used in operating activities | $34.6 million | $40.1 million |
There are no meaningful product gross margins to report because the company has not generated product revenue. Operating expenses declined by $2.6 million year over year. Lower R&D spending reflected completion of the vancomycin study wind-down; lower G&A expense primarily reflected the closure of the Denmark office and related activities. Net loss narrowed by $4.9 million, helped by a $2.2 million improvement in other income/expense, including higher interest income as rates rose.
At year-end, cash and cash equivalents were $52.1 million and short-term investments were $73.8 million, totaling $125.9 million; working capital was approximately $123.1 million. Current liabilities were $5.9 million. The company reported an accumulated deficit of $338.7 million. It stated that available cash and investments were sufficient for operations for the 12 months following issuance of the financial statements, while also warning that additional capital may be needed to advance development and commercialization.
Long-term debt was $26.1 million, with no current portion reported at year-end. The amended Silicon Valley Bank loan provides interest-only payments through April 2026, followed by principal and interest payments through April 2027, subject to terms and covenants. It is secured by substantially all company assets, with a negative pledge on intellectual property. Operating cash flow remained negative; investing cash flow was positive $52.6 million, primarily from net maturities and sales of short-term investments. Financing cash flow was approximately $0.1 million, compared with $120.8 million in 2021, when the company completed a public offering.
Material changes and notable items
- Net loss improved year over year, while operating expenses declined modestly; the company continued to have no product sales.
- Cash and short-term investments fell from $161.2 million at year-end 2021 to $125.9 million at year-end 2022, notwithstanding lower operating cash use. 2021 included approximately $122.2 million of net public-offering proceeds; no shares were sold under the Evercore at-the-market agreement in 2022.
- Debt was refinanced in April 2022 under an amended and restated $26.5 million facility. The year-end carrying amount was $26.1 million.
- Savara pursued manufacturing redundancy: it engaged potential second sources for drug substance and drug product. Commercial-scale validation and comparability remain important development tasks. Patheon’s filling-line transfer required validation work to be repeated in 2023.
- In March 2023, Silicon Valley Bank entered receivership. Savara said depositors, including the company, regained access to deposits and that it did not anticipate a material impact, while noting it was monitoring the loan agreement and broader banking conditions.
Outlook, risks, and contingencies
Management expects continued operating losses and significant R&D and manufacturing spending as it advances molgramostim. The company has no product revenue and may need additional financing; equity financing could dilute shareholders, while debt or partnerships could impose restrictions or require relinquishing rights. No specific revenue, profit, or cash-flow guidance was provided.
- Clinical and regulatory risk: IMPALA-2 could be delayed or fail to demonstrate efficacy or safety. The prior IMPALA study missed its primary endpoint, and regulatory approval is uncertain.
- Execution and supply risk: Savara relies on third parties, including Parexel for IMPALA-2 and external manufacturers for drug substance, finished product, and the nebulizer. The company estimated approximately $17–$20 million in remaining Parexel fees and pass-through expenses under the work order, assuming no material changes; a separate commitment disclosure estimated about $33.6 million over the course of the trial.
- Financing and debt risk: Loan covenants may constrain operations; a default could accelerate repayment. The company also cited potential banking-sector liquidity concerns and the SVB receivership.
- Commercial risk: Approval would not ensure market acceptance, adequate reimbursement, or profitability. Savara has limited marketing capabilities and no sales organization, and expects to consider partners in some markets.
- Intellectual property: The filing states Savara has no patent protection for molgramostim for aPAP and relies substantially on potential orphan-drug exclusivity, device-related rights, and proprietary manufacturing assets.
- Other contingencies: Approximately $2.8 million in contingent manufacturing, development, and nebulizer milestones were disclosed as not yet achieved, accrued, or payable at year-end; additional royalties may apply following commercialization. No material pending litigation was reported.
Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2022. The independent auditor issued an unqualified opinion on the financial statements; it did not audit internal-control effectiveness.
Important facts for investors to verify
- IMPALA-2 enrollment progress, trial conduct, endpoint results, and whether the projected topline timing remains achievable.
- Cash runway assumptions, future operating cash use, and the timing and terms of any additional financing.
- Current status of the SVB loan, its covenants, repayment schedule, and any successor-lender arrangements.
- Whether second-source manufacturing, commercial-scale validation, and comparability requirements are completed on schedule.
- The impact of the prior IMPALA primary-endpoint miss on regulatory expectations, and the company’s limited patent protection and reliance on exclusivity.
- Potential dilution and share overhang: year-end common shares outstanding were about 114.0 million, with substantial options, restricted stock units, and warrants also disclosed.